Advances and Applications of Cancer Organoids in Drug Screening and Personalized Medicine.

In recent years, the rapid emergence of 3D organoid technology has garnered significant attention from researchers. These miniature models accurately replicate the structure and function of human tissues and organs, offering more physiologically relevant platforms for cancer research. These intricate 3D structures not only serve as promising models for studying human cancer, but also significantly contribute to the advancement of various potential applications in the field of cancer research. To date, organoids have been efficiently constructed from both normal and malignant tissues originating from patients. Using such bioengineering platforms, simulations of infections and cancer processes, mutations and carcinogenesis can be achieved, and organoid technology is also expected to facilitate drug testing and personalized therapies. In conclusion, regenerative medicine has the potential to enhance organoid technology and current transplantation treatments by utilizing genetically identical healthy organoids as substitutes for irreversibly deteriorating diseased organs. This review explored the evolution of cancer organoids and emphasized the significant role these models play in fundamental research and the advancement of personalized medicine in oncology.

Yang Y ，Kong Y ，Cui J ，Hou Y ，Gu Z ，Ma C ... -  《-》

Organoid technology and applications in cancer research.

Xu H ，Lyu X ，Yi M ，Zhao W ，Song Y ，Wu K ... -  《Journal of Hematology & Oncology》

Tumor Organoid as a Drug Screening Platform for Cancer Research.

Arani RM ，Yousefi N ，Hamidieh AA ，Gholizadeh F ，Sisakht MM ... -  《-》

Patient-Derived Organoids for Precision Cancer Immunotherapy.

Cancer immunotherapy has revolutionized the way tumors are treated. Nevertheless, efficient and robust testing platforms are still missing, including clinically relevant human ex vivo tumor assays that allow pretreatment testing of cancer therapies and selection of the most efficient and safe therapy for a specific patient. In the case of immunotherapy, this testing platform would require not only cancer cells, but also the tumor microenvironment, including immune cells. Here, we discuss the applications of patient-derived tumor organoid cultures and the possibilities in using complex immune-organoid cultures to provide preclinical testing platforms for precision cancer immunotherapy.

Grönholm M ，Feodoroff M ，Antignani G ，Martins B ，Hamdan F ，Cerullo V ... -  《-》

Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen.

Primary tumor organoids are a robust model of individual human cancers and present a unique platform for patient-specific drug testing. Optical imaging is uniquely suited to assess organoid function and behavior because of its subcellular resolution, penetration depth through the entire organoid, and functional endpoints. Specifically, optical metabolic imaging (OMI) is highly sensitive to drug response in organoids, and OMI in tumor organoids correlates with primary tumor drug response. Therefore, an OMI organoid drug screen could enable accurate testing of drug response for individualized cancer treatment. The objective of this perspective is to introduce OMI and tumor organoids to a general audience in order to foster the adoption of these techniques in diverse clinical and laboratory settings.

Walsh AJ ，Cook RS ，Skala MC 《-》